Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Aleix Prat(Hospital Clínic de Barcelona), Joaquín Gavilá(Fundación Instituto Valenciano de Oncología), Xavier González(Breast Cancer Research Foundation), Antonio Llombart‐Cussac(MedSIR (Spain)), Miguel Gil‐Gil(GEICAM – Spanish Breast Cancer Group), Cristina Hernándo(Hospital Clínico Universitario de Valencia), Blanca González‐Farré(Hospital Clínic de Barcelona), Tomás Pascual(Breast Cancer Research Foundation), P. Céliz, Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Pedro L. Fernández, Patricia Galván(Vall d'Hebron Institute of Oncology), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Santiago González Santiago(Hospital San Pedro de Alcántara), Eduardo Martínez de Dueñas(Consorcio Hospitalario Provincial de Castellón), Raquel Bratos(MD Anderson Cancer Center Madrid), Vanesa Ortega, Núria Chic(Breast Cancer Research Foundation), Eva Ciruelos(Hospital Universitario 12 De Octubre), Patricia Villagrasa, Cristina Saura(Vall d'Hebron Hospital Universitari), Neus Ferrer(Hospital Universitario Son Espases), Yann Izarzugaza(Hospital Universitario Fundación Jiménez Díaz), Montserrat Muñoz-Mateu(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Álvaro Montaño(Hospital Universitario Virgen del Rocío), Sergio Hoyos(Hospital Universitario Rey Juan Carlos), Míriam Arumí(Vall d'Hebron Hospital Universitari), Rafael López‐López(Universidade de Santiago de Compostela), Juan Antonio Virizuela(Hospital Universitario Virgen Macarena), Beatriz Rojas(Centro Oncológico de Galicia)
Cited by 199
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k